<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262207</url>
  </required_header>
  <id_info>
    <org_study_id>DESCH AOI 2016</org_study_id>
    <nct_id>NCT03262207</nct_id>
  </id_info>
  <brief_title>Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours</brief_title>
  <acronym>GAMETH</acronym>
  <official_title>Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours: Potential Risks and Consequences for the Conceptus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data suggest that sperm cells carry an epigenetic message during spermatogenesis and
      that this message is crucial for the future development of the embryo. This epigenetic
      signature is notably represented by methylation of genes subjected to imprinting (GSI) and
      the methylation of transposable elements (TE). Data on the maintenance of the imprint and of
      the control of TE accompanying human gametogenesis in a context of adult germinal testicular
      cancers, seminomas, are extremely fragmentary for tumour tissues and inexistent for gametes.

      The aim of this study is to determine whether patients with seminomas in comparison with
      fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes.

      This study is based on the use of an existing collection of biological samples. 90 samples
      will be selected and split into 3 groups:

        -  Group 1: 30 sperm samples from patients with seminomatous testicular tumours

        -  Group 2: 30 sperm samples from fertile patients

        -  Group 3: 30 sperm samples from infertile patients

      After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they
      will be analysed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of methylation profiles in paternal genes subjected to imprinting (GSI)</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Seminomas</condition>
  <arm_group>
    <arm_group_label>testicular tumours</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>fertile</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>infertile</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Extraction genomic DNA</intervention_name>
    <arm_group_label>testicular tumours</arm_group_label>
    <arm_group_label>fertile</arm_group_label>
    <arm_group_label>infertile</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of methylation profiles of numerous GSI and TE</intervention_name>
    <arm_group_label>testicular tumours</arm_group_label>
    <arm_group_label>fertile</arm_group_label>
    <arm_group_label>infertile</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)</intervention_name>
    <arm_group_label>testicular tumours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Method of protein detection by immunostaining and flow cytometry</intervention_name>
    <arm_group_label>testicular tumours</arm_group_label>
    <arm_group_label>fertile</arm_group_label>
    <arm_group_label>infertile</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        seminomas
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biological samples from persons who have provided written consent

          -  biological samples of patients over 18 years old

          -  with testicular tumours/Fertile/Infertile

          -  Matched for age with patients suffering from testicular tumours

        Exclusion Criteria:

          -  biological samples of persons without national health insurance cover

          -  biological samples from patients with chronic hepatitis B or C or HIV infection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

